NDAORALCAPSULE
Approved
Oct 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOLECTIN DS (tolmetin sodium) is an oral nonsteroidal anti-inflammatory drug (NSAID) approved in 1979 for the treatment of rheumatoid arthritis, osteoarthritis, and other inflammatory conditions. It functions as a COX inhibitor to reduce pain, inflammation, and fever in patients with chronic musculoskeletal disorders.
LOE Approaching
With LOE approaching and competitive pressure of 30, this mature brand likely operates with a lean commercial infrastructure focused on managing decline rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TOLECTIN DS offers limited career growth potential given its mature lifecycle stage and approaching loss of exclusivity. Roles focus on portfolio management, cost optimization, and managing the transition to generics rather than innovation or brand building.
Product Manager (Legacy/Mature Products)Field Sales Representative
Worked on TOLECTIN DS at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.